FORM PTO-1449



LIST OF PATENTS AND OTHER ITEMS FOR APPLICANT'S **INFORMATION DISCLOSURE STATEMENT**

247/164 APPLICANT:

ATTY.

SERIAL NO.

09/433,418

Joel B. Epstein

GROUP:

(Use several sheets if necessary)

FILING DATE: November 4, 1999

CKET NO.

1614

imp	BU	Halliday, GM, Knight, BA, Muller, HK. Reduction In Murine Langerhans Cell ATPase Staining Following Topical But Not Systemic Treatment with Steroid and Non-Steroid Immunosuppressants. Br J Dermatol 1986; 114:83-89.
MB	BV	Mornington, B. The Place of Azathioprine in the Treatment of Auto-Immune Diseases. Leb Med J 1973; 26(1): 21-30.



EXAMINER:

ot Yet Assigned

VSI

DATE CONSIDERED:

03/16/01

EXAMINER: Initial if reference is considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include a copy of this form with next communication to applicant

FORM PTO-1449

THED ITEMS FOR ADDITION

.IST	OF PATENTS AND	OTHER ITEMS	FOR APPLICANT'S
	INFORMATION	DISCLOSURE S	TATEMENT

(Use several sheets if necessary)

ATTY. CKET NO.	SERIAL NO.
247/164	09/433,418
APPLICANT:	

Joel B. Epstein

FILING DATE:

November 4, 1999

GROUP: 1617

			U.S	S. PATENT DOCUMENTS			
EXAMINER INITIAL		DOCUMENT NUMBER DATE		NAME		SUB CLASS	FILING DATE
MB	AA	3,056,785	2/2/62	Hitchings et al.	260	252	3/21/60
	AB	4,996,193	2/26/91	Hewitt et al.	514	11	3/3/89
	AC	5,204,329	4/20/93	Ackerman et al.	514	15	6/11/90
	AD	5,310,545	5/10/94	Eisen FEB 1 7 2000	W 727	49	1/15/93
	AE	5,540,931	7/30/96	Hewitt et al.	424	434	6/24/94
	AF	5,637,616	6/10/97	Sharpe et al.	514	562	10/5/93
	AG	5,639,759	6/17/97	Magolda et al.	514	285	3/27/95
	AH	5,716,648	2/10/98	Halokov et al.	424	682	12/21/9
	ΑI	5,691,343	11/25/97	Sandborn	514	262	3/30/95
V	AJ	5,733,915	3/31/98	Sandborn et al.	514	262	3/30/95
MS	AK	5,905,081	5/18/99	Sandborn	514	262	8/1/97

FOREIGN PATENT DOCUMENTS							
EXAMINER INITIAL	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB	TRANICIATION	
					,		

	OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc.)						
MB	AL	Woo, SB, Lee, SJ, Schubert, MM. Graft-vshost disease. Crit Rev Oral Biol Med 1997; 8(2):201-216.					
	AM	Schubert, MM, Sullivan, KM. Recognition, incidence, and management of oral graft-versus-host disease. NCI Monogr 1990; (9):135-143.					
Ms	AN	Nakamura, S, Hiroki, A, Shinohara, M, et al. Oral involvement in chronic graft-versus-host disease after allogeneic bone marrow transplantation. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 1996; 82(5):556-563.					

EXAMINER:	Not Yet Assigned DATE CONSIDERED:	03/16/01

EXAMINER: Initial if reference is considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include a copy of this form with next communication to applicant

LIST OF PATENTS AND OTHER ITEMS FOR APPLICANT'S INFORMATION DISCLOSURE STATEMENT

ATTY. CKET NO.	SERIAL NO.	
247/164	09/433,418	
APPLICANT:		
Joel B. Epstein	·	
FILING DATE:	GROUP:	
November 4 1000	1614	

(Use several sheets if necessary)

1	1					
mp	AO	Epstein JB, Reece, DE. Topical cyclosporin A for treatment of oral chronic graft-versus-host disease. Bone Marrow Transplant 1994; 13:81-86.				
	AP	Epstein JB, Truelove, EL. Topical cyclosporin in a bioadhesive for treatment of oral lichenoid mucosal reaction Oral Surg Oral Med Oral Pathol Oral Radiol Endod 1996; 82:532-536.				
	AQ	Sandborn WJ. A review of immune modifier therapy for inflammatory bowel disease: azathio ine, 6-mercaptourine, cyclosporin, and methotrexate. Am J Gastroenterol 1996; 91(3):423-433.				
	AR	Winklestein A. The effects of azathioprine and 6-MP on immunity. J Immunopharmacol 1979; 1:429-454.				
	AS	Brogan M, Hiserodt J, Oliver M, et al. The effect of 6-mercaptopurine on natural killer-cell activities in Crohn's disease. J Clin Immunol 1985; 5:204-11.				
	AT	Brogan M, Stevens R, Hiserodt J, et al. Effects of 6-MP on the impaired in vivo humoral responsiveness in Crohn's disease. Gastroenterol 1984; 86:A1035.				
	AU	Lozada F. Prednisone and azathioprine in the treatment of patients with vesiculoerosive oral diseases. Oral Surg Oral Med Oral Pathol 1981; 52(3):257-260.				
	AV	Robinson JR, Lozada-Nur F, Frieden I. Oral pemphigus vulgaris. A review of the literature and a report on the management of 12 cases. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 1997; 84:349-355.				
	AW	Lear, JT, English, JSC. Erosive and generalized lichen planus responsive to azathioprine. Clin Exper Derm 1996; 21:56-57.				
	AX	Allen LV Jr, Erickson MA. Stability of acetazolamide, allopurinol, azathioprine, clonazepam, and flucytosine in extemporaneously compounded oral liquids. Am J Health-Syst Pharm 1996; 53:1944-1949.				
	AY	Eggleston DJ, Nally FF. Treatment of aphthous ulceration with topical azathioprine. A double blind trial. Br J Oral Surg 1972; 9(3):233-236.				
	AZ	Suchko VI, Mashchenko IS. Local use of an azathioprine suspension in a dimexide solution in the combined treatment of parodontosis. Stomologica (Mosk) 1981; 60(3): 28-30.				
	ВА	Elliot JH, Leibowitz HM. Chemotherapeutic immunosuppression of the corneal graft reaction. 3. Topical azathioprine. Arch Opthalmol 1966; 76(5):709-711.				
	BB	Mackay IR, Bignell JL, Smith PH, Crawford BA. Prevention of corneal-graft failure with the immunosuppressive drug azathioprine. Lancet 1967; 514 (2):479-482.				
	ВС	Choi PM, Targan SR. Immunomodulator therapy in inflammatory bowel disease. Dig Dis Sci 1994; 39(9):1885-1892.				
MS	BD	Stotland BR, Lichtenstein GR. Newer treatments for inflammatory bowel disease. Prim Care 1996; 3(3):577-608.				

EVALUED						
EXAMINER:	· / //	110 11	10 1	DATE CONSIDERED:		
	- 11	IND W.C.	121	DATE CONSIDERED:	- 1 - 1	/
	. 6	Not Yet Assigned			03/16	101
					- / - /	, ,

EXAMINER: Initially reference is considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include a copy of this form with next communication to applicant

FORM PTO 1110					
FORM PTO-1449			ATTY. CKET NO.	SERIAL NO.	
LIST OF DATE	NTS AND OTHER ITEMS FOR	IPE	247/164	09/433,418	
LIST OF PATER	NIS AND OTHER ITEMS FOR	POLICANTS	APPLICANT:		
INFOR	MATION DISCLOSURE STATE	Y 1	Joel B. Epstein	•	
		FEB 1 7 2000 0	FILING DATE:	GROUP:	
((Jse several sheets if necessary)	3	November 4 1000	1614	

1614

	$\overline{}$			
Wb	BE	Zins BJ, Sandborn WJ, McKinney JA, et al. A dose-ranging study of azathioprine pharmacokinetics after single-dose administration of a delayed-release oral formulation. J Clin Pharmacol 1997; 37:38-46.		
	BF	Van Os EC, Zins WJ, Sandborn WJ, et al. Azathioprine pharmacokinetics after intravenous, oral, delayed release oral and rectal foam administration. Gut 1996; 39:63-68.		
	BG	Epstein JB, Priddy RW, Sherlock CH. Hairy leukoplakia-like lesions in immunosuppressed patients following bone marrow transplantation. Transplantation 1988; 46:462-4.		
	ВН	Epstein JB, Sherlock CH, Wolber RA. Hairy leukoplakia after bone marrow transplantation. Oral Surg Oral Med Oral Pathol 1993; 75:690-5.		
	BI	Scully, C, Paes de Llmeida, O, Porter, SR, Gilkes, JJH. Pemphigus vulgaris: the manifestations and long-term management of 55 patients with oral lesions. Br J Dermatol 1999; 140:84-89.		
	ВЈ	Lever, WF. Pemphigus and pemphigoid. A review of the advances made since 1964. J Amer Acad Dermatol. 1979; 1(1):2-31.		
	BK	Anstey, A, Lear, JT. Azathioprine: clinical pharmacology and current indications in autoimmune disorders. BioDrugs 1998; 9(1):33-47.		
	BL	Glied, M, Rico, JM. Treatment of autoimmune blistering diseases. Dermatol Clin 1999; 17(2):431-330.		
	ВМ	Eisen, D, Ellis, CN, et al. Effect of Topical Cyclosporine Rinse on Oral Lichen Planus. New Engl J Med 1990; 323(5):290-294.		
	BN	Ho, VC and Conklin, RJ. Effect of Topical Cyclosporine Rinse on Oral Lichen Planus. New Engl J Med 1991; 325(6):435.		
	ВО	Eisen, D, Griffiths, CEM et al. Cyclosporin Wash for Oral Lichen Planus. Lancet 1990; 335:535-536.		
	ВР	Eisen, D, Ellis, CN, Voorhees, JJ. Topical cyclosporine for oral bullous disorders. J Amer Acad Dermatol 1990; 23(5):936-937.		
	BQ	Eisen, D, Ellis, CN. Topical Cyclosporine for Oral Mucosal Disorders. J Amer Acad Dermatol 1990; 23(6):1259-1264.		
	BR	Volc-Platzer, B, Hönigsmann, H et al. Photochemotherapy Improves Chronic Cutaneous Graft-Versus-Host Disease.		
	BS	Farthing, PM, Maragou, P et al. Characteristics Of The Oral Lesions In Patients With Cutaneous Recurrent Erythema Multiforme. J Oral Path Med 1995; 24:9-13.		
MB	Plauth, M, Jenss, H, Meyle, J. Oral Manifestations of Crohn's Disease: An Analysis of 79 Cases. Gastroenterol 1991; 13(1):29-71.			

EXAMINER:	My	X Yet Assig	Rv gned	DATE CONSIDERED:	63/16/01
EVALABLED	1 1.1 1.1				, , .

EXAMINER: Initial if reference is considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include a copy of this form with next communication to applicant